… risk factors for brain metastasis (BM) during the course of EGFR-TKIs therapy from EGFR-…
We retrospectively reviewed the records of 134 patients with EGFR-mutated advanced lung …

… on the use of approved TKIs for the treatment of brain metastases in patients with NSCLC. …
evaluating the activity of EGFR TKIs in NSCLC patients with brain metastases. EGFR TKIs …

… EGFR wild type NSCLC. A growing number of studies focused on the relevance between
EGFR mutation status and brain metastases (BM… six studies without EGFR-TKI treatment before …

… This retrospective study shows that the EGFR TKI erlotinib is active in patients with brain
metastases from NSCLC. We have observed an overall response rate of 26.4% in a series of 69 …

… -mutant NSCLCs with central nervous system (CNS) metastases and the role of radiotherapy
… EGFR-TKIs in patients with EGFR-mutant NSCLC with newly diagnosed brain metastases. …

… factor receptor (EGFR)–tyrosine kinase inhibitor (TKIs) plus … ) than EGFR-TKI alone as
first-line setting for patients with EGFR-… multiple brain metastases (BrMs) remains undetermined. …

… such as EGFR tyrosine kinase inhibitors (EGFR-TKI) … EGFR mutations but not specifically
for brain metastases, our findings are consistent with findings that 3rd generation of EGFR-TKI …

… Thus, in this study, we assessed the effect of EGFR TKIs in combination with WBRT on
EGFR-mutated NSCLC patients with BM. We expected to provide evidence for use of this …

… have inferior response to first- generation EGFR TKIs (40). In the present … EGFR mutations
had received adjuvant EGFR TKI, supporting the hypothesis of clone selection by EGFR TKI. …

… 18.8 [±9.2] months p = 0.760) nor was there a significant difference in time to brain
metastases for patients who received an EGFR-TKI or only chemotherapy before development of …